

THALLIUM IMAGING TEST FORM
(ETT/PERSANTINE/ADENOSINE)

Complete for each Thallium Imaging test performed. Send original to Thallium Core Lab and a copy to the Data Coordinating Center.

| | | | | | | | | |
|------------|---|---|---|--|--|--|--|--|
| Clinic No. | | | - | | | | | |
| ID No. | | | - | | | | | |
| Form Type | T | T | | | | | | |

PART I: IDENTIFICATION

1. Patient's NAME CODE: -----

fm8fday

2. Date of study: -----

Month Day Year

3. Identify this test: ----- (1) (2) (3)

ETT Persantine Adenosine

idtest2

4. Time of test:

thaltyp2

- Pre-discharge or within 5 days after hospital discharge ----- (1)
- Six-week follow-up (42 to 70 days) ----- (2)
- Follow-up Thallium (71 to 182 days) ----- (3)
- Other ----- (4)

5. Was test performed according to protocol guidelines? ----- (1) (2)

protthal

Yes No



| | |
|--|----------|
| A. Reason: (Check one.) | thalreas |
| Complications post-revascularization ----- | (1) |
| Clinical reason ----- | (2) |
| Protocol violation ----- | (3) |
| Other ----- | (4) |
| Specify: _____ | |

| | | | | | | | | |
|--------|--|--|---|--|--|--|--|--|
| ID No. | | | - | | | | | |
|--------|--|--|---|--|--|--|--|--|

PART II: TESTING

6. Total dose of Thallium administered? thaldos2 mCi

7. How long was exercise continued after injection of Thallium? thalexer sec.

8. Was Persantine administered? persadm
 (1) (2)
 Yes No
 ↓

A. Persantine infusion? persinf (1) (2)
 Yes No
 ↓

1) Total dose pinfdose mg

B. Oral Persantine? persoral (1) (2)
 Yes No
 ↓

1) Total dose podose mg

C. Was aminophylline given? aminoph (1) (2)
 Yes No
 ↓

1) Total dose amindose mg IV

9. Was Adenosine administered? adenadm (1) (2)
 Yes No
 ↓

A. Total dose adendose mg

B. Total infusion time adentime seconds

| | | | | | | | | |
|-----------|---|---|---|--|--|--|--|--|
| ID No. | | | - | | | | | |
| Form Type | T | T | | | | | | |

10. Was nitroglycerin given? ----- thalng ----- (1) (2)
 Yes No
 ↓

| | |
|--------------------------------|----------------------------|
| A. Total dose: (Complete one.) | |
| 1) | <u>thngiv</u> _____ mcg IV |
| 2) | <u>thngsl</u> _____ mg SL |

11. Which of the following Thallium imaging scans were obtained? (Answer each item.)

A. Immediate post-exercise ----- impost ----- Yes No
 (1) (2)

B. Delayed (2 to 2.5 hr) ----- imdelay ----- (1) (2)

C. Rest (24 hrs post exercise) ----- imrest ----- (1) (2)

| | | | | | | | | |
|-----------|---|---|---|--|--|--|--|--|
| ID No. | | | - | | | | | |
| Form Type | T | T | | | | | | |

PART III: DATA ON MAGNETIC TAPE

Complete necessary data in columns A through E.
 EX = Immediate D = delayed (2 to 2.5 hr)
 R = Rest (24 hrs) post-exercise

| | A. <u>Order*</u> <u>on tape</u> | B. <u>Military Time</u> <u>hours:minutes</u> | C. <u>Duration</u> <u>(minutes)</u> | D. <u>Actual</u> <u>Obliquity (°)</u> | E. <u>Counts/View</u> |
|--|---------------------------------------|--|---|---|--------------------------|
| 12. Field flood | ___ | | | | |
| 13. Bar phantom | ___ | | | | |
| 14. Injection site | ___ | ___:___ | 15 sec | | ___ K |
| 15. LAO EX (immediately Post EX) | ___ | ___:___ | ___ | ___ | ___ K |
| 16. LLAT EX | ___ | ___:___ | ___ | ___ | ___ K |
| 17. ANT EX | ___ | ___:___ | ___ | ___ | ___ K |
| 18. Breast marker LAO EX | ___ | | | | |
| 19. Breast marker LLAT EX | ___ | | | | |
| 20. Breast marker ANT EX | ___ | | | | |
| LAO D (delayed 2-2.5 hr) | ___ | ___:___ | ___ | ___ | ___ K |
| 22. LLAT D | ___ | ___:___ | ___ | ___ | ___ K |
| 23. ANT D | ___ | ___:___ | ___ | ___ | ___ K |
| 24. Breast marker LAO D | ___ | | | | |
| 25. Breast marker LLAT D | ___ | | | | |
| 26. Breast marker ANT D | ___ | | | | |
| 27. LAO R (24 hr) | ___ | ___:___ | ___ | ___ | ___ K |
| 28. LLAT R | ___ | ___:___ | ___ | ___ | ___ K |
| 29. ANT R | ___ | ___:___ | ___ | ___ | ___ K |
| 30. Breast marker LAO R | ___ | | | | |
| 31. Breast marker LLAT R | ___ | | | | |
| 32. Breast marker ANT R | ___ | | | | |

*Use 00 if not done.

| | | | | | | | |
|-----------|---|---|---|--|--|--|--|
| ID No. | | | - | | | | |
| Form Type | T | T | | | | | |




PART IV: VISUAL ANALYSIS

These data should only be interpreted from the exercise and 2 to 2 1/2 hour delayed imaging scans, not from the study performed 24 hours post exercise.

33. Enlarged, dilated heart? ----- (1) (2)
 Yes No

endihr

34. Visual segment analysis:

| | <u>Fixed</u> | <u>Partial Redistri- bution</u> | <u>Complete Redistri- bution</u> | <u>Normal</u> | <u>Reverse Redistri- bution</u> | <u>Un inter- pretable</u> | |
|--|-------------------|-------------------------------------|--------------------------------------|---------------|-------------------------------------|-------------------------------|-------------|
| A. LAO: | | | | | | | |
|  | 1) Upper septum | (1) | (2) | (3) | (4) | (5) | (6) laous |
| | 2) Lower septum | (1) | (2) | (3) | (4) | (5) | (6) laols |
| | 3) Apex | (1) | (2) | (3) | (4) | (5) | (6) laoapx |
| | 4) Inferolateral | (1) | (2) | (3) | (4) | (5) | (6) laoil |
| | 5) Posterolateral | (1) | (2) | (3) | (4) | (5) | (6) laopl |
| B. ANT: | | | | | | | |
|  | 1) Anterobasal | (1) | (2) | (3) | (4) | (5) | (6) antab |
| | 2) Anterolateral | (1) | (2) | (3) | (4) | (5) | (6) antal |
| | 3) Apex | (1) | (2) | (3) | (4) | (5) | (6) antapx |
| | 4) Apical septum | (1) | (2) | (3) | (4) | (5) | (6) antas |
| | 5) Inferoseptal | (1) | (2) | (3) | (4) | (5) | (6) antis |
| C. LLAT: | | | | | | | |
|  | 1) Anterobasal | (1) | (2) | (3) | (4) | (5) | (6) llatab |
| | 2) Anterior | (1) | (2) | (3) | (4) | (5) | (6) llatant |
| | 3) Apex | (1) | (2) | (3) | (4) | (5) | (6) llatapx |
| | 4) Inferior | (1) | (2) | (3) | (4) | (5) | (6) llatinf |
| | 5) Posterobasal | (1) | (2) | (3) | (4) | (5) | (6) llatpb |

| | | | | | | | | | |
|-----------|---|---|---|--|--|--|--|--|--|
| ID No. | | | - | | | | | | |
| Form Type | T | T | | | | | | | |

35. Abnormal lung uptake? ----- **ablung** (1) (2)
 Yes No
 ↓

| |
|--|
| A. Abnormality: abamt Mild to Moderate (1) Severe (2) |
|--|

36. Transient LV dilatation? ----- **tlbdilat** (1) (2)
 Yes No

37. Regions with reversible hypoperfusion: (Answer each item.)

| |
|---|
| <i>Only segments noted in Item 34 as having partial or complete redistribution should be counted.</i> |
|---|

| | | | |
|---|----------------|------------|-----------|
| A. Anterior (B ₁ , B ₂ , C ₁ , or C ₂) ----- | antisc | <u>Yes</u> | <u>No</u> |
| | | (1) | (2) |
| B. Septum (A ₁ or A ₂) ----- | sepisc | (1) | (2) |
| C. Lateral (A ₄ or A ₅) ----- | laticsc | (1) | (2) |
| D. Inferoapical (A ₃ contiguous with A ₂) ----- | iaisc | (1) | (2) |
| E. Inferior (B ₄ , B ₅ , C ₄ , or C ₅) ----- | infisc | (1) | (2) |
| F. Non-contiguous apical (A ₃ , B ₃ , or C ₃) ----- | apcisc | (1) | (2) |
| (Counted as separate region only if non-contiguous with other region(s) with reversible hypoperfusion.) | | | |

38. High risk*:

| | | | |
|--|---------------|------------|-----------|
| A. Abnormal lung uptake (Question 35) and ≥ 1 region with reversible hypoperfusion (Question 37, at least 1 item answered YES) ----- | alured | <u>Yes</u> | <u>No</u> |
| | | (1)* | (2) |
| B. ≥ 2 regions with reversible hypoperfusion (Question 37, at least 2 items answered YES) ----- | twoish | (1)* | (2) |

*If A or B is answered YES, patient has reached a defined study end point.

| | | | | | | | | |
|-----------|---|---|---|--|--|--|--|--|
| ID No. | | | - | | | | | |
| Form Type | T | T | | | | | | |

PART V: TECHNICAL PROBLEMS

39. Did patient motion interfere with the study? ----- **motion** (1) (2)
 Yes No
 ↓

A. Which views? (Check all that apply.)

| | | | |
|---------------|---------------------|--------------------|---------------------|
| | a. | b. | c. |
| | EX | D | R |
| 1) ANT ----- | motantex (1) | motantd (1) | motantr (1) |
| 2) LAO ----- | motlaox (1) | motlaod (1) | motlaor (1) |
| 3) LLAT ----- | motllatx (1) | motllat (1) | motllatr (1) |

40. Were there positioning difficulties? ----- **position** (1) (2)
 Yes No
 ↓

A. Which views? (Check all that apply.)

| | | | |
|---------------|---------------------|--------------------|---------------------|
| | a. | b. | c. |
| | EX | D | R |
| 1) ANT ----- | posantex (1) | posantd (1) | posantr (1) |
| 2) LAO ----- | poslaox (1) | poslaod (1) | poslaor (1) |
| 3) LLAT ----- | posllatx (1) | posllat (1) | posllatr (1) |

41. Are there breast attenuation or other attenuation artifacts? ----- **breast** (1) (2)
 Yes No
 ↓

thalfem

A. Is patient female? ----- Yes (1) No (2)

PART VI: ADMINISTRATIVE MATTERS

42. Research Coordinator:

Signature: _____ T3 Staff No.: _____

43. Date form and diskette mailed to Thallium Core Lab: -----
 _____ - _____ - _____
 Month Day Year

| | | | | | | | | |
|-----------|---|---|---|--|--|--|--|--|
| ID No. | | | - | | | | | |
| Form Type | T | T | | | | | | |

T3 Form 8F: Variables from earlier revisions
[Revision 0 form not available]

IDTEST Revision 1 Item 3; Revision 2 Item 3
Identify this test:
1=ETT 2=Persantine

THALPER Revision 0 Item 5
Thallium or Persantine?
1=Thallium

THALLIUM Revision 0 Item 5A
Thallium 201 GI
1=Yes

THALTYPE Revision 1 Item 4
Time of test:
1=Pre-discharge or within 5 days of hospital discharge
2=Six-week follow-up
3=Other

IMAGE Revision 1 Item 10
Was Thallium imaging complete?
1=Yes 2=No

T3B form8f**The CONTENTS Procedure**

| | | | |
|-----------------------|--------------------------------|------------------------------|------|
| Data Set Name: | WORK.FORM8F | Observations: | 1622 |
| Member Type: | DATA | Variables: | 80 |
| Engine: | V8 | Indexes: | 0 |
| Created: | 12:53 Friday, February 6, 2004 | Observation Length: | 344 |
| Last Modified: | 12:53 Friday, February 6, 2004 | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

| ----Alphabetic List of Variables and Attributes---- | | | | | |
|---|----------|------|-----|-----|--|
| # | Variable | Type | Len | Pos | Label |
| 47 | ABAMT | Num | 4 | 164 | f8Fq35A: Lung uptake abnormality |
| 46 | ABLUNG | Num | 4 | 160 | f8Fq35: Abnormal lung uptake |
| 20 | ADENADM | Num | 4 | 72 | f8Fq9: Adenosine |
| 21 | ADENDOSE | Num | 5 | 321 | f8Fq9A: Adenosine dose (mg) |
| 22 | ADENTIME | Num | 5 | 326 | f8Fq9B: Adenosine infusion time (secs) |
| 55 | ALURED | Num | 4 | 196 | f8Fq38A: Abnormal lung uptake & reversib |
| 19 | AMINDOSE | Num | 5 | 316 | f8Fq8C1: Aminophylline dose (mg IV) |
| 18 | AMINOPH | Num | 4 | 68 | f8Fq8C: Aminophylline |
| 36 | ANTAB | Num | 4 | 120 | f8Fq34B1: ANT analysis anterobasal |
| 37 | ANTAL | Num | 4 | 124 | f8Fq34B2: ANT analysis anterolateral |
| 38 | ANTAPX | Num | 4 | 128 | f8Fq34B3: ANT analysis apex |
| 39 | ANTAS | Num | 4 | 132 | f8Fq34B4: ANT analysis apical septum |
| 40 | ANTIS | Num | 4 | 136 | f8Fq34B5: ANT analysis inferoseptal |
| 49 | ANTISC | Num | 4 | 172 | f8Fq37A: Reversible hypoperfusion anteri |
| 54 | APCISC | Num | 4 | 192 | f8Fq37F: Reversible hypoperfusion non-co |
| 77 | BREAST | Num | 4 | 284 | f8Fq41: Breast attenuation |
| 30 | ENDIHRT | Num | 4 | 96 | f8Fq33: Enlarged heart |
| 80 | FM8FDAY | Num | 8 | 16 | f8Fq2: Days to study |
| 2 | FMTYP | Char | 4 | 292 | Form Type |
| 52 | IAISC | Num | 4 | 184 | f8Fq37D: Reversible hypoperfusion infero |
| 3 | IDTEST | Num | 4 | 24 | f8Fq3 (rev 0): Identify test |
| 4 | IDTEST2 | Num | 4 | 28 | f8Fq3: Identify test |

(06FEB04--12:53)

T3B form8f**The CONTENTS Procedure**

| -----Alphabetic List of Variables and Attributes----- | | | | | |
|--|-----------------|-------------|------------|------------|--|
| # | Variable | Type | Len | Pos | Label |
| 26 | IMAGE | Num | 4 | 80 | f8Fq10 (rev 0): Thallium imaging complet |
| 28 | IMDELAY | Num | 4 | 88 | f8Fq11B: Delayed scan |
| 27 | IMPOST | Num | 4 | 84 | f8Fq11A: Immed post-exercise scan |
| 29 | IMREST | Num | 4 | 92 | f8Fq11C: Rest scan |
| 53 | INFISC | Num | 4 | 188 | f8Fq37E: Reversible hypoperfusion inferi |
| 33 | LAOAPX | Num | 4 | 108 | f8Fq34A3: LAO analysis apex |
| 34 | LAOIL | Num | 4 | 112 | f8Fq34A4: LAO analysis inferolateral |
| 32 | LAOLS | Num | 4 | 104 | f8Fq34A2: LAO analysis lower Septum |
| 35 | LAOPL | Num | 4 | 116 | f8Fq34A5: LAO analysis posterolateral |
| 31 | LAOUS | Num | 4 | 100 | f8Fq34A1: LAO analysis upper septum |
| 51 | LATISC | Num | 4 | 180 | f8Fq37C: Reversible hypoperfusion latera |
| 41 | LLATAB | Num | 4 | 140 | f8Fq34C1: LLAT analysis anterobasal |
| 42 | LLATANT | Num | 4 | 144 | f8Fq34C2: LLAT analysis anterior |
| 43 | LLATAPX | Num | 4 | 148 | f8Fq34C3: LLAT analysis apex |
| 44 | LLATINF | Num | 4 | 152 | f8Fq34C4: LLAT analysis inferior |
| 45 | LLATPB | Num | 4 | 156 | f8Fq34C5: LLAT analysis posterobasal |
| 59 | MOTANTD | Num | 4 | 212 | f8Fq39A1B: Motion ANT D |
| 58 | MOTANTEX | Num | 4 | 208 | f8Fq39A1A: Motion ANT EX |
| 60 | MOTANTR | Num | 4 | 216 | f8Fq39A1C: Motion ANT R |
| 57 | MOTION | Num | 4 | 204 | f8Fq39: Patient motion interfered with s |
| 62 | MOTLAOD | Num | 4 | 224 | f8Fq39A2B: Motion LAO D |
| 61 | MOTLAOEX | Num | 4 | 220 | f8Fq39A2A: Motion LAO EX |
| 63 | MOTLAOR | Num | 4 | 228 | f8Fq39A2C: Motion LAO R |
| 65 | MOTLLATD | Num | 4 | 236 | f8Fq39A3B: Motion LLAT D |
| 66 | MOTLLATR | Num | 4 | 240 | f8Fq39A3C: Motion LLAT R |
| 64 | MOTLLATX | Num | 4 | 232 | f8Fq39A3A: Motion LLAT EX |
| 79 | NEWID | Num | 8 | 8 | Patient Identification |
| 13 | PERSADM | Num | 4 | 56 | f8Fq8: Persantine administered |
| 14 | PERSINF | Num | 4 | 60 | f8Fq8A: Persantine infusion |
| 16 | PERSORAL | Num | 4 | 64 | f8Fq8B: Oral persantine |
| 15 | PINFDOSE | Num | 5 | 306 | f8Fq8A1: Persantine infusion dose (mg) |

(06FEB04--12:53)

T3B form8f**The CONTENTS Procedure**

| -----Alphabetic List of Variables and Attributes----- | | | | | |
|--|-----------------|-------------|------------|------------|--|
| # | Variable | Type | Len | Pos | Label |
| 17 | PODOSE | Num | 5 | 311 | f8Fq8B1: Oral persantine dose (mg) |
| 69 | POSANTD | Num | 4 | 252 | f8Fq40A1B: Position ANT D |
| 68 | POSANTEX | Num | 4 | 248 | f8Fq40A1A: Position ANT EX |
| 70 | POSANTR | Num | 4 | 256 | f8Fq40A1C: Position ANT R |
| 67 | POSITION | Num | 4 | 244 | f8Fq40: Positioning difficulties |
| 72 | POSLAOD | Num | 4 | 264 | f8Fq40A2B: Position LAO D |
| 71 | POSLAOEX | Num | 4 | 260 | f8Fq40A2A: Position LAO EX |
| 73 | POSLAOR | Num | 4 | 268 | f8Fq40A2C: Position LAO R |
| 75 | POSLLATD | Num | 4 | 276 | f8Fq40A3B: Position LLAT D |
| 76 | POSLLATR | Num | 4 | 280 | f8Fq40A3C: Position LLAT R |
| 74 | POSLLATX | Num | 4 | 272 | f8Fq40A3A: Position LLAT EX |
| 7 | PROTHAL | Num | 4 | 40 | f8Fq5: Test according to protocol |
| 1 | REV | Num | 8 | 0 | Revision |
| 50 | SEPISC | Num | 4 | 176 | f8Fq37B: Reversible hypoperfusion septum |
| 9 | THALDOS2 | Num | 5 | 296 | f8Fq6: Total dose of thallium (mCi) |
| 10 | THALEXER | Num | 5 | 301 | f8Fq7: Exercise time after injection |
| 78 | THALFEM | Num | 4 | 288 | f8Fq41A: Patient female |
| 12 | THALLIUM | Num | 4 | 52 | f8Fq5A (rev 0): Thallium 201 GI |
| 23 | THALNG | Num | 4 | 76 | f8Fq10: Nitroglycerin |
| 11 | THALPER | Num | 4 | 48 | f8Fq5 (rev 0): Thallium or Persantine |
| 8 | THALREAS | Num | 4 | 44 | f8Fq5A: Reason not according to protocol |
| 6 | THALTYP2 | Num | 4 | 36 | f8Fq4: Time of test |
| 5 | THALTYPE | Num | 4 | 32 | f8Fq4 (rev 0): Time of test |
| 24 | THNGIV | Num | 5 | 331 | f8Fq10A1: Nitroglycerin IV dose (mcg IV) |
| 25 | THNGSL | Num | 5 | 336 | f8Fq10A2: Nitroglycerin SL dose (mg SL) |
| 48 | TLVDILAT | Num | 4 | 168 | f8Fq36: Transient LV dilatation |
| 56 | TWOISH | Num | 4 | 200 | f8Fq38B: 2 or more regions reversible hy |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|----------|------------------------------|-------|------|------|-------|
| REV | Revision | 0 | 211 | 13.0 | |
| | | 1 | 271 | 16.7 | |
| | | 2 | 902 | 55.6 | |
| | | 3 | 238 | 14.7 | |
| FMTYP | Form Type | TT01 | 1334 | 82.2 | |
| | | TT02 | 277 | 17.1 | |
| | | TT03 | 9 | 0.6 | * |
| | | TT04 | 2 | 0.1 | * |
| IDTEST | f8Fq3 (rev 0): Identify test | . | 449 | 27.7 | |
| | | 1 | 1043 | 64.3 | |
| | | 2 | 130 | 8.0 | |
| IDTEST2 | f8Fq3: Identify test | . | 1384 | 85.3 | |
| | | 1 | 217 | 13.4 | |
| | | 2 | 19 | 1.2 | * |
| | | 3 | 2 | 0.1 | * |
| THALTYP2 | f8Fq4: Time of test | . | 482 | 29.7 | |
| | | 1 | 937 | 57.8 | |
| | | 2 | 175 | 10.8 | |
| | | 3 | 9 | 0.6 | * |
| | | 4 | 19 | 1.2 | * |
| THALTYPE | f8Fq4 (rev 0): Time of test | . | 1140 | 70.3 | |
| | | 1 | 370 | 22.8 | |
| | | 2 | 108 | 6.7 | |
| | | 3 | 4 | 0.2 | * |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|-----------------|--|--------------|----------|----------|-----------------|
| PROTTHAL | f8Fq5: Test according to protocol | . | 1 | 0.1 | * |
| | | 1 | 1563 | 96.4 | |
| | | 2 | 58 | 3.6 | |
| THALPER | f8Fq5 (rev 0): Thallium or Persantine | . | 1411 | 87.0 | |
| | | 1 | 211 | 13.0 | |
| THALLIUM | f8Fq5A (rev 0): Thallium 201 GI | . | 1411 | 87.0 | |
| | | 1 | 211 | 13.0 | |
| THALREAS | f8Fq5A: Reason not according to protocol | . | 1564 | 96.4 | |
| | | 1 | 2 | 0.1 | * |
| | | 2 | 11 | 0.7 | * |
| | | 3 | 12 | 0.7 | * |
| | | 4 | 33 | 2.0 | |
| PERSADM | f8Fq8: Persantine administered | . | 212 | 13.1 | |
| | | 1 | 149 | 9.2 | |
| | | 2 | 1261 | 77.7 | |
| PERSINF | f8Fq8A: Persantine infusion | . | 1261 | 77.7 | |
| | | 1 | 135 | 8.3 | |
| | | 2 | 226 | 13.9 | |
| PERSORAL | f8Fq8B: Oral persantine | . | 1262 | 77.8 | |
| | | 1 | 24 | 1.5 | |
| | | 2 | 336 | 20.7 | |
| AMINOPH | f8Fq8C: Aminophylline | . | 1262 | 77.8 | |
| | | 1 | 54 | 3.3 | |
| | | 2 | 306 | 18.9 | |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|-----------------|--|--------------|----------|----------|-----------------|
| ADENADM | f8Fq9: Adenosine | . | 1385 | 85.4 | |
| | | 1 | 3 | 0.2 | * |
| | | 2 | 234 | 14.4 | |
| IMAGE | f8Fq10 (rev 0): Thallium imaging complet | . | 1140 | 70.3 | |
| | | 1 | 355 | 21.9 | |
| | | 2 | 127 | 7.8 | |
| THALNG | f8Fq10: Nitroglycerin | 1 | 40 | 2.5 | |
| | | 2 | 1582 | 97.5 | |
| IMPOST | f8Fq11A: Immed post-exercise scan | . | 354 | 21.8 | |
| | | 1 | 1260 | 77.7 | |
| | | 2 | 8 | 0.5 | * |
| IMDELAY | f8Fq11B: Delayed scan | . | 354 | 21.8 | |
| | | 1 | 1250 | 77.1 | |
| | | 2 | 18 | 1.1 | * |
| IMREST | f8Fq11C: Rest scan | . | 354 | 21.8 | |
| | | 1 | 182 | 11.2 | |
| | | 2 | 1086 | 67.0 | |
| ENDIHRT | f8Fq33: Enlarged heart | . | 217 | 13.4 | |
| | | 1 | 156 | 9.6 | |
| | | 2 | 1249 | 77.0 | |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|----------|--------------------------------------|-------|------|------|-------|
| LAOUS | f8Fq34A1: LAO analysis upper septum | . | 9 | 0.6 | * |
| | | 1 | 103 | 6.4 | |
| | | 2 | 71 | 4.4 | |
| | | 3 | 102 | 6.3 | |
| | | 4 | 1313 | 80.9 | |
| | | 5 | 6 | 0.4 | * |
| | | 6 | 18 | 1.1 | * |
| LAOLS | f8Fq34A2: LAO analysis lower Septum | . | 7 | 0.4 | * |
| | | 1 | 85 | 5.2 | |
| | | 2 | 73 | 4.5 | |
| | | 3 | 136 | 8.4 | |
| | | 4 | 1299 | 80.1 | |
| | | 5 | 8 | 0.5 | * |
| | | 6 | 14 | 0.9 | * |
| LAOAPX | f8Fq34A3: LAO analysis apex | . | 7 | 0.4 | * |
| | | 1 | 252 | 15.5 | |
| | | 2 | 135 | 8.3 | |
| | | 3 | 150 | 9.2 | |
| | | 4 | 1042 | 64.2 | |
| | | 5 | 19 | 1.2 | * |
| | | 6 | 17 | 1.0 | * |
| LAOIL | f8Fq34A4: LAO analysis inferolateral | . | 7 | 0.4 | * |
| | | 1 | 172 | 10.6 | |
| | | 2 | 76 | 4.7 | |
| | | 3 | 88 | 5.4 | |
| | | 4 | 1242 | 76.6 | |
| | | 5 | 24 | 1.5 | |
| | | 6 | 13 | 0.8 | * |

(06FEB04--12:53)

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|----------|---------------------------------------|-------|------|------|-------|
| LAOPL | f8Fq34A5: LAO analysis posterolateral | . | 7 | 0.4 | * |
| | | 1 | 131 | 8.1 | |
| | | 2 | 37 | 2.3 | |
| | | 3 | 58 | 3.6 | |
| | | 4 | 1355 | 83.5 | |
| | | 5 | 21 | 1.3 | |
| | | 6 | 13 | 0.8 | * |
| ANTAB | f8Fq34B1: ANT analysis anterobasal | . | 8 | 0.5 | * |
| | | 1 | 35 | 2.2 | |
| | | 2 | 29 | 1.8 | |
| | | 3 | 38 | 2.3 | |
| | | 4 | 1487 | 91.7 | |
| | | 5 | 9 | 0.6 | * |
| | | 6 | 16 | 1.0 | * |
| ANTAL | f8Fq34B2: ANT analysis anterolateral | . | 8 | 0.5 | * |
| | | 1 | 67 | 4.1 | |
| | | 2 | 45 | 2.8 | |
| | | 3 | 57 | 3.5 | |
| | | 4 | 1422 | 87.7 | |
| | | 5 | 8 | 0.5 | * |
| | | 6 | 15 | 0.9 | * |
| ANTAPX | f8Fq34B3: ANT analysis apex | . | 8 | 0.5 | * |
| | | 1 | 288 | 17.8 | |
| | | 2 | 115 | 7.1 | |
| | | 3 | 98 | 6.0 | |
| | | 4 | 1083 | 66.8 | |
| | | 5 | 17 | 1.0 | * |
| | | 6 | 13 | 0.8 | * |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|----------|--------------------------------------|-------|------|------|-------|
| ANTAS | f8Fq34B4: ANT analysis apical septum | . | 8 | 0.5 | * |
| | | 1 | 197 | 12.1 | |
| | | 2 | 88 | 5.4 | |
| | | 3 | 100 | 6.2 | |
| | | 4 | 1205 | 74.3 | |
| | | 5 | 11 | 0.7 | * |
| | | 6 | 13 | 0.8 | * |
| ANTIS | f8Fq34B5: ANT analysis inferoseptal | . | 8 | 0.5 | * |
| | | 1 | 163 | 10.0 | |
| | | 2 | 54 | 3.3 | |
| | | 3 | 75 | 4.6 | |
| | | 4 | 1286 | 79.3 | |
| | | 5 | 18 | 1.1 | * |
| | | 6 | 18 | 1.1 | * |
| LLATAB | f8Fq34C1: LLAT analysis anterobasal | . | 11 | 0.7 | * |
| | | 1 | 75 | 4.6 | |
| | | 2 | 30 | 1.8 | |
| | | 3 | 47 | 2.9 | |
| | | 4 | 1418 | 87.4 | |
| | | 5 | 9 | 0.6 | * |
| | | 6 | 32 | 2.0 | |
| LLATANT | f8Fq34C2: LLAT analysis anterior | . | 10 | 0.6 | * |
| | | 1 | 145 | 8.9 | |
| | | 2 | 60 | 3.7 | |
| | | 3 | 79 | 4.9 | |
| | | 4 | 1282 | 79.0 | |
| | | 5 | 14 | 0.9 | * |
| | | 6 | 32 | 2.0 | |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|-----------------|--------------------------------------|--------------|----------|----------|-----------------|
| LLATAPX | f8Fq34C3: LLAT analysis apex | . | 9 | 0.6 | * |
| | | 1 | 292 | 18.0 | |
| | | 2 | 104 | 6.4 | |
| | | 3 | 78 | 4.8 | |
| | | 4 | 1090 | 67.2 | |
| | | 5 | 18 | 1.1 | * |
| | | 6 | 31 | 1.9 | |
| LLATINF | f8Fq34C4: LLAT analysis inferior | . | 8 | 0.5 | * |
| | | 1 | 138 | 8.5 | |
| | | 2 | 79 | 4.9 | |
| | | 3 | 75 | 4.6 | |
| | | 4 | 1285 | 79.2 | |
| | | 5 | 19 | 1.2 | * |
| | | 6 | 18 | 1.1 | * |
| LLATPB | f8Fq34C5: LLAT analysis posterobasal | . | 9 | 0.6 | * |
| | | 1 | 161 | 9.9 | |
| | | 2 | 46 | 2.8 | |
| | | 3 | 60 | 3.7 | |
| | | 4 | 1306 | 80.5 | |
| | | 5 | 14 | 0.9 | * |
| | | 6 | 26 | 1.6 | |
| ABLUNG | f8Fq35: Abnormal lung uptake | . | 3 | 0.2 | * |
| | | 1 | 216 | 13.3 | |
| | | 2 | 1403 | 86.5 | |
| ABAMT | f8Fq35A: Lung uptake abnormality | . | 1405 | 86.6 | |
| | | 1 | 197 | 12.1 | |
| | | 2 | 20 | 1.2 | * |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|-----------------|--|--------------|----------|----------|-----------------|
| TLVDILAT | f8Fq36: Transient LV dilatation | . | 214 | 13.2 | |
| | | 1 | 78 | 4.8 | |
| | | 2 | 1330 | 82.0 | |
| ANTISC | f8Fq37A: Reversible hypoperfusion anteri | . | 8 | 0.5 | * |
| | | 1 | 201 | 12.4 | |
| | | 2 | 1413 | 87.1 | |
| SEPISC | f8Fq37B: Reversible hypoperfusion septum | . | 8 | 0.5 | * |
| | | 1 | 244 | 15.0 | |
| | | 2 | 1370 | 84.5 | |
| LATISC | f8Fq37C: Reversible hypoperfusion latera | . | 8 | 0.5 | * |
| | | 1 | 180 | 11.1 | |
| | | 2 | 1434 | 88.4 | |
| IAISC | f8Fq37D: Reversible hypoperfusion infero | . | 8 | 0.5 | * |
| | | 1 | 135 | 8.3 | |
| | | 2 | 1479 | 91.2 | |
| INFISC | f8Fq37E: Reversible hypoperfusion inferi | . | 8 | 0.5 | * |
| | | 1 | 286 | 17.6 | |
| | | 2 | 1328 | 81.9 | |
| APCISC | f8Fq37F: Reversible hypoperfusion non-co | . | 8 | 0.5 | * |
| | | 1 | 203 | 12.5 | |
| | | 2 | 1411 | 87.0 | |
| ALURED | f8Fq38A: Abnormal lung uptake & reversib | . | 6 | 0.4 | * |
| | | 1 | 145 | 8.9 | |
| | | 2 | 1471 | 90.7 | |

(06FEB04--12:53)

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|-----------------|--|--------------|----------|----------|-----------------|
| TWOISH | f8Fq38B: 2 or more regions reversible hy | . | 6 | 0.4 | * |
| | | 1 | 359 | 22.1 | |
| | | 2 | 1257 | 77.5 | |
| MOTION | f8Fq39: Patient motion interfered with s | . | 3 | 0.2 | * |
| | | 1 | 46 | 2.8 | |
| | | 2 | 1573 | 97.0 | |
| MOTANTEX | f8Fq39A1A: Motion ANT EX | . | 1619 | 99.8 | |
| | | 1 | 3 | 0.2 | * |
| MOTANTD | f8Fq39A1B: Motion ANT D | . | 1618 | 99.8 | |
| | | 1 | 4 | 0.2 | * |
| MOTANTR | f8Fq39A1C: Motion ANT R | . | 1621 | 99.9 | |
| | | 1 | 1 | 0.1 | * |
| MOTLAOEX | f8Fq39A2A: Motion LAO EX | . | 1621 | 99.9 | |
| | | 1 | 1 | 0.1 | * |
| MOTLAOD | f8Fq39A2B: Motion LAO D | . | 1620 | 99.9 | |
| | | 1 | 2 | 0.1 | * |
| MOTLAOR | f8Fq39A2C: Motion LAO R | . | 1621 | 99.9 | |
| | | 1 | 1 | 0.1 | * |
| MOTLLATX | f8Fq39A3A: Motion LLAT EX | . | 1604 | 98.9 | |
| | | 1 | 18 | 1.1 | * |
| MOTLLATD | f8Fq39A3B: Motion LLAT D | . | 1597 | 98.5 | |
| | | 1 | 25 | 1.5 | |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|-----------------|----------------------------------|--------------|----------|----------|-----------------|
| MOTLLATR | f8Fq39A3C: Motion LLAT R | . | 1618 | 99.8 | |
| | | 1 | 4 | 0.2 | * |
| POSITION | f8Fq40: Positioning difficulties | . | 3 | 0.2 | * |
| | | 1 | 61 | 3.8 | |
| | | 2 | 1558 | 96.1 | |
| POSANTEX | f8Fq40A1A: Position ANT EX | . | 1618 | 99.8 | |
| | | 1 | 4 | 0.2 | * |
| POSANTD | f8Fq40A1B: Position ANT D | . | 1617 | 99.7 | |
| | | 1 | 5 | 0.3 | * |
| POSANTR | f8Fq40A1C: Position ANT R | . | 1620 | 99.9 | |
| | | 1 | 2 | 0.1 | * |
| POSLAOEX | f8Fq40A2A: Position LAO EX | . | 1603 | 98.8 | |
| | | 1 | 19 | 1.2 | * |
| POSLAOD | f8Fq40A2B: Position LAO D | . | 1607 | 99.1 | |
| | | 1 | 15 | 0.9 | * |
| POSLAOR | f8Fq40A2C: Position LAO R | . | 1615 | 99.6 | |
| | | 1 | 7 | 0.4 | * |
| POSLLATX | f8Fq40A3A: Position LLAT EX | . | 1595 | 98.3 | |
| | | 1 | 27 | 1.7 | |
| POSLLATD | f8Fq40A3B: Position LLAT D | . | 1594 | 98.3 | |
| | | 1 | 28 | 1.7 | |

T3B form8f

| Variable | Label | Value | N | % | <= 20 |
|-----------------|----------------------------|--------------|----------|----------|-----------------|
| POSLLATR | f8Fq40A3C: Position LLAT R | . | 1613 | 99.4 | |
| | | 1 | 9 | 0.6 | * |
| BREAST | f8Fq41: Breast attenuation | . | 2 | 0.1 | * |
| | | 1 | 314 | 19.4 | |
| | | 2 | 1306 | 80.5 | |
| THALFEM | f8Fq41A: Patient female | . | 1301 | 80.2 | |
| | | 1 | 291 | 17.9 | |
| | | 2 | 30 | 1.8 | |

T3B form8f

| Variable | Label | N | Percentile | Value | n | <= 20 |
|----------|--|------|------------|-------|-----|-------|
| THALDOS2 | f8Fq6: Total dose of thallium (mCi) | 1620 | 5 | 2 | 245 | |
| | | | 25 | 2.3 | 172 | |
| | | | 50 | 2.7 | 422 | |
| | | | 75 | 3 | 498 | |
| | | | 95 | 3.3 | 207 | |
| | | | 100 | 4.5 | 76 | |
| THALEXER | f8Fq7: Exercise time after injection | 1606 | 5 | 0 | 114 | |
| | | | 25 | 60 | 938 | |
| | | | 50 | 60 | 0 | * |
| | | | 75 | 90 | 186 | |
| | | | 95 | 120 | 327 | |
| | | | 100 | 720 | 41 | |
| PINFDOSE | f8Fq8A1: Persantine infusion dose (mg) | 135 | 5 | 30 | 8 | * |
| | | | 25 | 38 | 27 | |
| | | | 50 | 45 | 40 | |
| | | | 75 | 50 | 38 | |
| | | | 95 | 61.8 | 16 | * |
| | | | 100 | 74.3 | 6 | * |
| PODOSE | f8Fq8B1: Oral persantine dose (mg) | 24 | 5 | 300 | 21 | |
| | | | 25 | 300 | 0 | * |
| | | | 50 | 300 | 0 | * |
| | | | 75 | 300 | 0 | * |
| | | | 95 | 375 | 2 | * |
| | | | 100 | 600 | 1 | * |

T3B form8f

| Variable | Label | N | Percentile | Value | n | <= 20 |
|----------|--|----|------------|-------|----|-------|
| AMINDOSE | f8Fq8C1: Aminophylline dose (mg IV) | 54 | 5 | 50 | 5 | * |
| | | | 25 | 75 | 12 | * |
| | | | 50 | 125 | 24 | |
| | | | 75 | 125 | 0 | * |
| | | | 95 | 325 | 11 | * |
| | | | 100 | 500 | 2 | * |
| ADENDOSE | f8Fq9A: Adenosine dose (mg) | 3 | 5 | 2.6 | 1 | * |
| | | | 25 | 2.6 | 0 | * |
| | | | 50 | 51.6 | 1 | * |
| | | | 75 | 65.6 | 1 | * |
| | | | 95 | 65.6 | 0 | * |
| | | | 100 | 65.6 | 0 | * |
| ADENTIME | f8Fq9B: Adenosine infusion time (secs) | 3 | 5 | 40 | 1 | * |
| | | | 25 | 40 | 0 | * |
| | | | 50 | 360 | 1 | * |
| | | | 75 | 420 | 1 | * |
| | | | 95 | 420 | 0 | * |
| | | | 100 | 420 | 0 | * |
| THNGIV | f8Fq10A1: Nitroglycerin IV dose (mcg IV) | 3 | 5 | 0 | 2 | * |
| | | | 25 | 0 | 0 | * |
| | | | 50 | 0 | 0 | * |
| | | | 75 | 60 | 1 | * |
| | | | 95 | 60 | 0 | * |
| | | | 100 | 60 | 0 | * |

T3B form8f

| Variable | Label | N | Percentile | Value | n | <= 20 |
|----------|---|----|------------|-------|----|-------|
| THNGSL | f8Fq10A2: Nitroglycerin SL dose (mg SL) | 39 | 5 | 0.3 | 7 | * |
| | | | 25 | 0.4 | 24 | |
| | | | 50 | 0.4 | 0 | * |
| | | | 75 | 0.4 | 0 | * |
| | | | 95 | 0.8 | 8 | * |
| | | | 100 | 0.8 | 0 | * |

T3B form8f

| Variable | Label | N | Mean | Std Dev | Minimum | Maximum |
|-----------------|----------------------|----------|-------------|----------------|----------------|----------------|
| FM8FDAY | f8Fq2: Days to study | 1622 | 20.0 | 41.8 | 1.0 | 840.0 |